The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...

For patients with heart failure (HF), a greater focus on medication management may be needed in order to mitigate HF exacerbations caused by certain ...

“Beneficial pediatric obesity treatment response yielded enduring health benefits, markedly lowering future morbidity and mortality risks in young adulthood,” the authors write. Several authors ...

HealthDay News — Heart disease continues to be a leading cause of death, according to a report from the American Heart Association published online January 27 in Circulation.

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for SL1009 (sodium dichloroacetate oral solution) for the treatment of pyruvate dehydrogenase complex ...